Yazar "Isikdogan, A." seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis(Elsevier, 2022) Isikdogan, A.; Turk, H.; Bilir, C.; Sendur, M.; Karabulut, B.; Artac, M.; Cicin, I.[Abstract Not Available]Öğe Gemcitabine alone versus gemcitabine plus cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic adenocarcinoma: A retrospective analysis of multicenter study(Amer Soc Clinical Oncology, 2011) Inal, A.; Isikdogan, A.; Kos, T.; Algin, E.; Gumus, M.; Dikilitas, M.; Elkiran, E. T.[Abstract Not Available]Öğe Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA)(Elsevier Sci Ltd, 2015) Ozkan, M.; Cicin, I.; Ozaslan, E.; Benekli, M.; Oksuzoglu, B.; Kocer, M.; Isikdogan, A.[Abstract Not Available]Öğe Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study(Elsevier, 2021) Arslan, C.; Kefeli, U.; Yildirim, E.; Isikdogan, A.; Karadurmus, N.; Karabulut, B.; Cicin, I.[Abstract Not Available]
